Changes

In most of the researches in obesity, weight is considered as the main parameter. However, it is a very superficial parameter. Weight reduction to make the obese person thin is a primary goal in general practice. However, the most crucial concern in treating an obese person is not to make the person thin but to transform an unhealthy obese person to a healthy obese person. [Su.Sa. Sutra Sthana 35/34] If the person has adipose tissue with optimum quality (meda sara), it is challenging to reduce weight. Similarly, in hyperhomocysteinemia, one should see whether the patient is with optimal quality of blood tissue (rakta sara), before treating the person. So while treating obesity and metabolic syndrome through [[Ayurveda]], the targets should be different, and the biomarkers should be more specific.

In most of the researches in obesity, weight is considered as the main parameter. However, it is a very superficial parameter. Weight reduction to make the obese person thin is a primary goal in general practice. However, the most crucial concern in treating an obese person is not to make the person thin but to transform an unhealthy obese person to a healthy obese person. [Su.Sa. Sutra Sthana 35/34] If the person has adipose tissue with optimum quality (meda sara), it is challenging to reduce weight. Similarly, in hyperhomocysteinemia, one should see whether the patient is with optimal quality of blood tissue (rakta sara), before treating the person. So while treating obesity and metabolic syndrome through [[Ayurveda]], the targets should be different, and the biomarkers should be more specific.

==Selection of biomarker==

===Selection of biomarker===

The selection of biomarker depends on the type of disorder and drug used for therapy. The correct selection of biomarker sheds light on the mode of action of that particular drug.  The medicines described for the treatment of obesity vary in their mode of action. The different medicines for reducing body tissues (lekhana) act differently. Some medicines work on fatty liver; some on skeletal muscles; some have insulin sensitizing action; and some have anti oxidant activities specific to the adipose tissue ([[meda dhatu]]). So depending on the underlying pathology and drug, the biomarker should be selected. If we suspect inflammatory involvement, then the best biomarker is either Adiponectin or high sensitive c reactive protein (HSCRP). Adiponectin level suggests the presence of inflammation, tendency of atherogenesis, or presence of insulin resistance at the cellular level. In different types of metabolic disorders like hypercholesterolemia, hyperhomocysteinemia etc. the specific biomarker should be selected.

The selection of biomarker depends on the type of disorder and drug used for therapy. The correct selection of biomarker sheds light on the mode of action of that particular drug.  The medicines described for the treatment of obesity vary in their mode of action. The different medicines for reducing body tissues (lekhana) act differently. Some medicines work on fatty liver; some on skeletal muscles; some have insulin sensitizing action; and some have anti oxidant activities specific to the adipose tissue ([[meda dhatu]]). So depending on the underlying pathology and drug, the biomarker should be selected. If we suspect inflammatory involvement, then the best biomarker is either Adiponectin or high sensitive c reactive protein (HSCRP). Adiponectin level suggests the presence of inflammation, tendency of atherogenesis, or presence of insulin resistance at the cellular level. In different types of metabolic disorders like hypercholesterolemia, hyperhomocysteinemia etc. the specific biomarker should be selected.